• CRISPR/Cas9 Genome Editing

CRISPR/Cas9 Genome Editing

We leveraged our expertise in CRISPR/Cas9 technology to develop affordable and convenient “do-it-yourself” kits for generating your own genetically modified human and mouse cell line models. The CRISPRCLEAR™ kits for cell line model generation are available in two formats: (1) Custom designed kits for knock-in, knockout or point mutation models for a specific genomic locus; (2) Ready-to-use kits for transgene knock-in into a safe harbor locus in any cell line, including iPSCs, blood-lineage cells and mouse cell lines. These kits are manufactured in our ISO:9001 quality management system certified facility in the USA using very optimized protocols and stringent quality control criteria.

CRISPR/Cas9 Genome Editing Categories

Cell Line Model Generation

Our CRISPRCLEAR™ Cell Line Model kits offer an affordable and efficient way to genetically engineer human or mouse cell lines in your own laboratory.

Cell Line Model Generation

Products and Services
Catalog ID#Product Name SizePriceQTY
$1,700.00
$1,000.00
$1,800.00
$1,000.00
$1,000.00
$1,800.00
$1,200.00

7 Items

per page
Publications

CRISPR Cell Line Genome Editing

  • Selvan, N., George, S., Serajee, F. J., Shaw, M., Hobson, L., Kalscheuer, V. M., ... & Schwartz, C. E. (2018). O-GlcNAc transferase missense mutations linked to X-linked intellectual disability deregulate genes involved in cell fate determination and signaling. Journal of Biological Chemistry, jbc-RA118.

  • Smalley, E. (2018). FDA warns public of dangers of DIY gene therapy.https://doi.org/10.1038/nbt0218-119

  • Chai, S., Wan, X., Ramirez-Navarro, A., Tesar, P. J., Kaufman, E. S., Ficker, E., ... & Deschênes, I. (2018). Physiological genomics identifies genetic modifiers of long QT syndrome type 2 severity. The Journal of clinical investigation128(3).

  • Boi, S., Ferrell, M. E., Zhao, M., Hasenkrug, K. J., & Evans, L. H. (2018). Mouse APOBEC3 expression in NIH 3T3 cells mediates hypermutation of AKV murine leukemia virus. Virology518, 377-384. https://doi.org/10.1016/j.virol.2018.03.014.

  • Molinski, S. V., et al. (2017). Orkambi® and amplifier cotherapy improves function from a rare CFTR mutation in geneedited cells and patient tissue. EMBO Molecular Medicine, e201607137.

  • Petrovic, P. B. (2017). Myosin Phosphatase Rho-interacting Protein Regulates DDR1-mediated Collagen Tractional Remodeling (Doctoral dissertation, University of Toronto (Canada).

  • Peng, L., Zhang, H., Hao, Y., Xu, F., Yang, J., Zhang, R., ... & Chen, C. (2016). Reprogramming macrophage orientation by microRNA 146b targeting transcription factor IRF5. EBioMedicine14, 83-96.

  • Hu, J. K., Crampton, J. C., Locci, M., & Crotty, S. (2016). CRISPR-mediated Slamf1Δ/Δ Slamf5Δ/Δ Slamf6Δ/Δ triple gene disruption reveals NKT cell defects but not T follicular helper cell defects. PloS one11(5), e0156074.

  • Smalley, E. (2016). CRISPR mouse model boom, rat model renaissance. Nature Biotechnology. 34, 893–894.

  • Baker, M. (2014). Gene editing at CRISPR speed. Nature biotechnology32(4), 309-313.

CRISPR Technology:

AAVS1 locus

  • Varshney, GK., et al. (2015). Genome research, 25(7), 1030-1042.

  • Tiyaboonchai, A., et al. (2014) Stem cell research, 12(3), 630-637

  • Sadelain, M., et al. (2012). Cancer, 12(1), 51-58.

H11 locus

Rosa26 locus

Technical Details

SCHEMATIC-CRISPR

We also offer products and kits using our proprietary TARGATT™ technology for efficient, site-specific gene insertion. The TARGATT™ products are an ideal toolkit for efficient knock-in of large transgenes which are usually not very efficient using CRISPR/Cas9.

Choose the right gene editing technology

Applied StemCell also uses a propriety site-specific integrase-based gene editing technology, TARGATT™ for large fragment (up to 20 kb) knock-in in safe harbor locus. The complementary TARGATT™ and CRISPR/Cas9 technologies can be used together to generate advanced cell line and animal models very efficiently and effectively.

Project Purpose

CRISPR/Cas9

TARGATT™

Knock-Out (KO)

Yes

 

Point Mutation

Yes

 

Conditional KO

Yes

 

Knock-In

(<200 Nucleotide ssODN Donor)

Yes

 

Knock-In Transgenes in

Safe Harbor Loci (>2kb)

Challenging

(but limitations on size)

Yes

 (up to 20kb)

Knock-In

 (Plasmid DNA)

Challenging

(but limitations on size)

Yes

 (2 steps: KI docking site; KI transgene) 

Have Questions?

An Applied StemCell technical expert is happy to help, contact us today!